Regeneron Pharmaceuticals' Equity Average rose 602.46% to $31.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.1 billion, marking a year-over-year increase of 602.46%. This contributed to the annual value of $30.3 billion for FY2025, which is 955.02% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Equity Average of $31.1 billion as of Q4 2025, which was up 602.46% from $30.4 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Equity Average registered a high of $31.1 billion during Q4 2025, and its lowest value of $11.5 billion during Q1 2021.
In the last 5 years, Regeneron Pharmaceuticals' Equity Average had a median value of $24.1 billion in 2023 and averaged $23.6 billion.
Within the past 5 years, the most significant YoY rise in Regeneron Pharmaceuticals' Equity Average was 7033.3% (2021), while the steepest drop was 94.91% (2021).
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Equity Average stood at $18.0 billion in 2021, then rose by 22.42% to $22.1 billion in 2022, then rose by 15.36% to $25.4 billion in 2023, then increased by 15.33% to $29.3 billion in 2024, then grew by 6.02% to $31.1 billion in 2025.
Its Equity Average was $31.1 billion in Q4 2025, compared to $30.4 billion in Q3 2025 and $29.7 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value